Interplay between NRF2 post-translational modifications and protein-protein interactions: Perspectives from emerging structural and functional evidence

Article type: Review Article

Keywords: NRF2, PPIs, KEAP1, PTM-Code, Regulatory mechanisms

Authors: Adem Ozleyen, Seda Savranoglu Kulabas, Miroslav Novak, Milena Cichoń, Cristina Matas De Las Heras, Tadashi Honda, Richard G. Doveston, Albena T. Dinkova-Kostova, Anna Grochot-Przeczek, Tugba Boyunegmez Tumer

Affiliations: Health Institutes of Turkiye, Turkiye Biotechnology Institute, Ankara, 06270, Turkiye; Department of Immunology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkiye; Division of Cancer Research, School of Medicine, University of Dundee, Scotland, United Kingdom; Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland; Doctoral School of Exact and Natural Sciences, Jagiellonian University, Kraków, Poland; Leicester Institute for Structural and Chemical Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom; School of Chemistry, University of Leicester, Leicester, LE1 7RH, United Kingdom; Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, NY, USA; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Molecular Biology and Genetics, Faculty of Arts and Science, Canakkale Onsekiz Mart University, Canakkale, 17020, Turkiye

License: © 2026 The Authors CC BY 4.0 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Article links: DOI: 10.1016/j.abb.2026.110847  |  PubMed: 42097191  |  PMC: PMC13271694

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (439 KB)

References

1. M. Yamamoto, T.W. Kensler, H. Motohashi. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol. Rev., 2018. [DOI | PubMed]
2. P. Moi, K. Chan, I. Asunis, A. Cao, Y.W. Kan. Isolation of NF-E2-related factor 2 (nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci., 1994. [DOI | PubMed]
3. A. Cuadrado, E. Cazalla, A. Bach, B. Bathish, S.D. Naidu, G.M. DeNicola, A.T. Dinkova-Kostova, R. Fernández-Ginés, A. Grochot-Przeczek, J.D. Hayes, T.W. Kensler, R. León, K.T. Liby, M.G. López, G. Manda, A.K. Shivakumar, H. Hakomäki, J.A. Moerland, H. Motohashi, A.I. Rojo, G.P. Sykiotis, K. Taguchi, Á.M. Valverde, M. Yamamoto, A.-L. Levonen. Health position paper and redox perspectives – bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol., 2025. [DOI]
4. X. He, M.G. Chen, G.X. Lin, Q. Ma. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2·Keap1·Cul3 complex and recruiting Nrf2·Maf to the antioxidant response element enhancer. J. Biol. Chem., 2006. [DOI | PubMed]
5. L.B. Nam, Y.-S. Keum. Binding partners of NRF2: functions and regulatory mechanisms. Arch. Biochem. Biophys., 2019. [DOI]
6. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, Y. Nabeshima. An Nrf2/Small maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 1997. [DOI | PubMed]
7. P. Minguez, I. Letunic, L. Parca, P. Bork. PTMcode: a database of known and predicted functional associations between post-translational modifications in proteins. Nucleic Acids Res., 2013. [DOI | PubMed]
8. P. Rada, A.I. Rojo, S. Chowdhry, M. McMahon, J.D. Hayes, A. Cuadrado. SCF/β-TrCP promotes glycogen synthase kinase 3-Dependent degradation of the Nrf2 transcription factor in a Keap1-Independent manner. Mol. Cell Biol., 2011. [DOI | PubMed]
9. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, M. Yamamoto. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 1999. [DOI]
10. T. Liu, Y.-F. Lv, J.-L. Zhao, Q.-D. You, Z.-Y. Jiang. Regulation of Nrf2 by phosphorylation: consequences for biological function and therapeutic implications. Free Radic. Biol. Med., 2021. [DOI | PubMed]
11. K. Taguchi, H. Motohashi, M. Yamamoto. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells, 2011. [DOI | PubMed]
12. H. Wang, K. Liu, M. Geng, P. Gao, X. Wu, Y. Hai, Y. Li, Y. Li, L. Luo, J.D. Hayes, X.J. Wang, X. Tang. RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res., 2013. [DOI | PubMed]
13. B.S. Dhanoa, T. Cogliati, A.G. Satish, E.A. Bruford, J.S. Friedman. Update on the Kelch-like (KLHL) gene family. Hum. Genomics, 2013. [DOI | PubMed]
14. S. Lo, X. Li, M.T. Henzl, L.J. Beamer, M. Hannink. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J., 2006. [DOI | PubMed]
15. G.A. Shilovsky, D.V. Dibrova. 2023. [DOI]
16. K.I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, M. Yamamoto. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell Biol., 2006. [DOI | PubMed]
17. L.M. Zipper, R.T. Mulcahy. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J. Biol. Chem., 2002. [DOI | PubMed]
18. M. McMahon, N. Thomas, K. Itoh, M. Yamamoto, J.D. Hayes. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a “tethering”; mechanism: a TWO-SITE INTERACTION MODEL FOR THE Nrf2-Keap1 COMPLEX. J. Biol. Chem., 2006. [DOI | PubMed]
19. L. Baird, D. Llères, S. Swift, A.T. Dinkova-Kostova. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc. Natl. Acad. Sci., 2013. [DOI | PubMed]
20. M. McMahon, N. Thomas, K. Itoh, M. Yamamoto, J.D. Hayes. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem., 2004. [DOI | PubMed]
21. D. Stewart, E. Killeen, R. Naquin, S. Alam, J. Alam. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem., 2003. [DOI | PubMed]
22. T. Nguyen, P.J. Sherratt, H.-C. Huang, C.S. Yang, C.B. Pickett. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: DEGRADATION OF Nrf2 BY THE 26 S PROTEASOME. J. Biol. Chem., 2003. [DOI | PubMed]
23. M.-K. Kwak, K. Itoh, M. Yamamoto, T.W. Kensler. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell Biol., 2002. [DOI | PubMed]
24. J. Zhao, B. Zhang, S. Li, L. Zeng, Y. Chen, J. Fang. Mangiferin increases Nrf2 protein stability by inhibiting its ubiquitination and degradation in human HL60 myeloid leukemia cells. Int. J. Mol. Med., 2014. [DOI | PubMed]
25. W. Chen, Z. Sun, X.-J. Wang, T. Jiang, Z. Huang, D. Fang, D.D. Zhang. Direct interaction between Nrf2 and p21Cip1/WAF1 upregulates the Nrf2-Mediated antioxidant response. Mol. Cell, 2009. [DOI | PubMed]
26. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, M. V Brock, S. Biswal. Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med., 2006. [DOI]
27. R. Wang, J. An, F. Ji, H. Jiao, H. Sun, D. Zhou. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun., 2008. [DOI | PubMed]
28. K. Taguchi, M. Yamamoto. The KEAP1–NRF2 system in cancer. Front. Oncol., 2017
29. L.D. Goldstein, J. Lee, F. Gnad, C. Klijn, A. Schaub, J. Reeder, A. Daemen, C.E. Bakalarski, T. Holcomb, D.S. Shames, R.J. Hartmaier, J. Chmielecki, S. Seshagiri, R. Gentleman, D. Stokoe. Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep., 2016. [DOI | PubMed]
30. H.-C. Huang, T. Nguyen, C.B. Pickett. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem., 2002. [DOI | PubMed]
31. D.A. Bloom, A.K. Jaiswal. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:Quinone Oxidoreductase-1 gene expression. J. Biol. Chem., 2003. [DOI | PubMed]
32. S.B. Cullinan, D. Zhang, M. Hannink, E. Arvisais, R.J. Kaufman, J.A. Diehl. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol., 2003. [DOI | PubMed]
33. N. Saptarshi, L.F. Porter, L. Paraoan. PERK/EIF2AK3 integrates endoplasmic reticulum stress-induced apoptosis, oxidative stress and autophagy responses in immortalised retinal pigment epithelial cells. Sci. Rep., 2022. [DOI]
34. H.M. Coley, E. Hatzimichael, S. Blagden, I. Mcneish, A. Thompson, T. Crook, N. Syed. Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer. 2012
35. M.S. Joo, S.-B. Shin, E.J. Kim, H.J. Koo, H. Yim, S.G. Kim. Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21cip1. FASEB J., 2019. [DOI | PubMed]
36. 36L. Manfreda, F. Rruga, A. Zanolli, B. Marzullo, L. Vettore, M. Canton, C. Marchioro, E. Rampazzo, E. Mariotto, D.A. Tennant, Nrf2 activation is required for chemotherapy resistance acquisition in medulloblastoma via metabolic and redox adaptation, Available at SSRN 5186264 (n.d.). 10.2139/ssrn.5186264.
37. J.R. Graff, A.M. McNulty, K.R. Hanna, B.W. Konicek, R.L. Lynch, S.N. Bailey, C. Banks, A. Capen, R. Goode, J.E. Lewis, L. Sams, K.L. Huss, R.M. Campbell, P.W. Iversen, B.L. Neubauer, T.J. Brown, L. Musib, S. Geeganage, D. Thornton. The protein kinase Cβ–Selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human Colon cancer and glioblastoma xenografts. Cancer Res., 2005. [DOI | PubMed]
38. C. Querfeld, M.A. Rizvi, T.M. Kuzel, J. Guitart, A. Rademaker, S.S. Sabharwal, N.L. Krett, S.T. Rosen. The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-Cell lymphoma cell lines through the AKT pathway. J. Invest. Dermatol., 2006. [DOI | PubMed]
39. M.A. Rizvi, K. Ghias, K.M. Davies, C. Ma, F. Weinberg, H.G. Munshi, N.L. Krett, S.T. Rosen. Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Therapeut., 2006. [DOI]
40. W. Li, J. Zhang, L. Flechner, T. Hyun, A. Yam, T.F. Franke, J.H. Pierce. Protein kinase C-α overexpression stimulates akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. Oncogene, 1999. [DOI | PubMed]
41. D. Lu, J. Huang, A. Basu. Protein kinase Cϵ activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis Factor-α-induced cell death. J. Biol. Chem., 2006. [DOI | PubMed]
42. L. Wang, Y. Chen, P. Sternberg, J. Cai. Essential roles of the PI3 kinase/akt pathway in regulating Nrf2-Dependent antioxidant functions in the RPE. Investig. Ophthalmol. Vis. Sci., 2008. [DOI | PubMed]
43. I. Gopallawa, L.E. Kuek, N.D. Adappa, J.N. Palmer, R.J. Lee. Small-molecule Akt-activation in airway cells induces NO production and reduces IL-8 transcription through Nrf-2. Respir. Res., 2021. [DOI | PubMed]
44. A. De Blasio, R. Di Fiore, G. Pratelli, R. Drago-Ferrante, C. Saliba, S. Baldacchino, G. Grech, C. Scerri, R. Vento, G. Tesoriere. A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells. J. Cell. Physiol., 2020. [DOI | PubMed]
45. D.R. Alessi, F. Barry Caudwell, M. Andjelkovic, B.A. Hemmings, P. Cohen. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett., 1996. [DOI | PubMed]
46. Z. Mounir, J.L. Krishnamoorthy, S. Wang, B. Papadopoulou, S. Campbell, W.J. Muller, M. Hatzoglou, A.E. Koromilas. Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway. Sci. Signal., 2011. [DOI]
47. M. Blaustein, D. Pérez-Munizaga, M.A. Sánchez, C. Urrutia, A. Grande, G. Risso, A. Srebrow, J. Alfaro, A. Colman-Lerner. Modulation of the akt pathway reveals a novel link with PERK/eIF2α, which is relevant during hypoxia. PLoS One, 2013. [DOI]
48. J.-W. Lee, Y.-J. Choi, J.-H. Park, J.-Y. Sim, Y.-S. Kwon, H.J. Lee, S.-S. Kim, W. Chun. 3, 4, 5-Trihydroxycinnamic acid inhibits lipopolysaccharide-induced inflammatory response through the activation of Nrf2 pathway in BV2 microglial cells. Biomol. Ther. (Seoul)., 2013. [PubMed]
49. J.-W. Park, J.-H. Oh, D. Hwang, S.-M. Kim, J.-H. Min, J.-Y. Seo, W. Chun, H.J. Lee, S.-R. Oh, J.-W. Lee. 4, 5-Trihydroxycinnamic acid exerts anti-inflammatory effects on TNF-α/IFN-γ-stimulated HaCaT cells. Mol. Med. Rep., 2021. [PubMed]
50. L. Ma, J. Liu, X. Zhang, J. Qi, W. Yu, Y. Gu. p38 MAPK-Dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med. Oncol., 2015. [DOI | PubMed]
51. R.P. P, B. John. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev., 2004. [DOI | PubMed]
52. C. Cabane, A.-S. Coldefy, K. Yeow, B. Dérijard. The p38 pathway regulates akt both at the protein and transcriptional activation levels during myogenesis. Cell. Signal., 2004. [DOI | PubMed]
53. D.D. Zhang, M. Hannink. Distinct cysteine residues in Keap1 are required for Keap1-Dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol., 2003. [DOI | PubMed]
54. A.L. Eggler, G. Liu, J.M. Pezzuto, R.B. van Breemen, A.D. Mesecar. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci., 2005. [DOI | PubMed]
55. J. Abramson, J. Adler, J. Dunger, R. Evans, T. Green, A. Pritzel, O. Ronneberger, L. Willmore, A.J. Ballard, J. Bambrick, S.W. Bodenstein, D.A. Evans, C.-C. Hung, M. O’Neill, D. Reiman, K. Tunyasuvunakool, Z. Wu, A. Žemgulytė, E. Arvaniti, C. Beattie, O. Bertolli, A. Bridgland, A. Cherepanov, M. Congreve, A.I. Cowen-Rivers, A. Cowie, M. Figurnov, F.B. Fuchs, H. Gladman, R. Jain, Y.A. Khan, C.M.R. Low, K. Perlin, A. Potapenko, P. Savy, S. Singh, A. Stecula, A. Thillaisundaram, C. Tong, S. Yakneen, E.D. Zhong, M. Zielinski, A. Žídek, V. Bapst, P. Kohli, M. Jaderberg, D. Hassabis, J.M. Jumper. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 2024. [DOI | PubMed]
56. A. Meyer, M. Schartl. Gene and genome duplications in vertebrates: the one-to-four (-to-eight in fish) rule and the evolution of novel gene functions. Curr. Opin. Cell Biol., 1999. [DOI | PubMed]
57. J.Y. Chan, M.-C. Cheung, P. Moi, K. Chan, Y.W. Kan. Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization. Hum. Genet., 1995. [DOI | PubMed]
58. A. Kobayashi, E. Ito, T. Toki, K. Kogame, S. Takahashi, K. Igarashi, N. Hayashi, M. Yamamoto. Molecular cloning and functional characterization of a new cap’n’ collar family transcription factor Nrf3. J. Biol. Chem., 1999. [DOI | PubMed]
59. G.M. Castiglione, Z. Xu, L. Zhou, E.J. Duh. Adaptation of the master antioxidant response connects metabolism, lifespan and feather development pathways in birds. Nat. Commun., 2020. [DOI | PubMed]
60. G.P. Sykiotis, D. Bohmann. Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in drosophila. Dev. Cell, 2008. [DOI | PubMed]
61. N.M. Danielli, R. Trevisan, D.F. Mello, K. Fischer, V.S. Deconto, A. Bianchini, A.C.D. Bainy, A.L. Dafre. Contrasting effects of a classic Nrf2 activator, tert-butylhydroquinone, on the glutathione-related antioxidant defenses in Pacific oysters, Crassostrea gigas. Mar. Environ. Res., 2017. [DOI | PubMed]
62. A. Kozeleková, A. Náplavová, T. Brom, N. Gašparik, J. Šimek, J. Houser, J. Hritz. Phosphorylated and phosphomimicking variants may differ—A case study of 14-3-3 protein. Front. Chem., 2022
63. H.Y. Zhao, M. Xin, S.Q. Zhang. Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Dev. Res., 2023. [DOI]
64. D. Frescas, M. Pagano. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat. Rev. Cancer, 2008. [DOI | PubMed]
65. R.M.R. Feldman, C.C. Correll, K.B. Kaplan, R.J. Deshaies. A complex of Cdc4p, Skp1p, and Cdc53p/Cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell, 1997. [DOI | PubMed]
66. D. Skowyra, K.L. Craig, M. Tyers, S.J. Elledge, J.W. Harper. F-Box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell, 1997. [DOI | PubMed]
67. P. Rada, A.I. Rojo, N. Evrard-Todeschi, N.G. Innamorato, A. Cotte, T. Jaworski, J.C. Tobón-Velasco, H. Devijver, M.F. García-Mayoral, F. Van Leuven, J.D. Hayes, G. Bertho, A. Cuadrado. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol. Cell Biol., 2012. [DOI | PubMed]
68. S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, J.D. Hayes. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene, 2013. [DOI | PubMed]
69. D.A.E. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995. [DOI | PubMed]
70. A. Ortega-Molina, M. Serrano. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metabol., 2013. [DOI]
71. K. Taguchi, I. Hirano, T. Itoh, M. Tanaka, A. Miyajima, A. Suzuki, H. Motohashi, M. Yamamoto. Nrf2 enhances cholangiocyte expansion in pten-deficient livers. Mol. Cell Biol., 2014. [DOI | PubMed]
72. A.I. Rojo, P. Rada, M. Mendiola, A. Ortega-Molina, K. Wojdyla, A. Rogowska-Wrzesinska, D. Hardisson, M. Serrano, A. Cuadrado. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid. Redox Signaling, 2014. [DOI]
73. A. Cuadrado. Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP. Free Radic. Biol. Med., 2015. [DOI | PubMed]
74. A. Kuga, K. Tsuchida, H. Panda, M. Horiuchi, A. Otsuki, K. Taguchi, F. Katsuoka, M. Suzuki, M. Yamamoto. The β-TrCP-Mediated pathway cooperates with the Keap1-Mediated pathway in Nrf2 degradation in vivo. Mol. Cell Biol., 2022. [DOI]
75. R. Fernández-Ginés, J.A. Encinar, J.D. Hayes, B. Oliva, M.I. Rodríguez-Franco, A.I. Rojo, A. Cuadrado. An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter β-TrCP delivers anti-inflammatory responses in mouse liver. Redox Biol., 2022. [DOI]
76. R. Fernández-Ginés, J.A. Encinar, M. Escoll, D. Carnicero-Senabre, J. Jiménez-Villegas, Á.J. García-Yagüe, Á. González-Rodríguez, I. Garcia-Martinez, A.M. Valverde, A.I. Rojo, A. Cuadrado. Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH. Redox Biol., 2024. [DOI]
77. N. Roy, T. Wyseure, I.-C. Lo, J. Metzger, C.L. Eissler, S.M. Bernard, I. Bok, A.N. Snead, A. Parker, J.C. Green, J. Inloes, S.R. Jacinto, B. Kuenzi, B.D. Horning, N. Ibrahim, S. Grabow, H. Panda, D.P. Bhatt, S. Saeidi, P. Zolkind, Z. Rush, K. Negri, H.N. Williams, E. Walton, M.K. Pastuszka, J.J. Sigler, E. Tran, K. Hee, J. McLaughlin, G. Ambrus-Aikelin, J. Pollock, R.T. Abraham, T.M. Kinsella, G.M. Simon, M.B. Major, D.S. Weinstein, M.P. Patricelli. Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular glue. bioRxiv, 2024. [DOI]
78. H. Jiang, H. Xiong, S.-X. Gu, M. Wang. E3 ligase ligand optimization of clinical PROTACs. Front. Chem., 2023
79. G. Sathe, G.P. Sapkota. Proteomic approaches advancing targeted protein degradation. Trends Pharmacol. Sci., 2023. [DOI | PubMed]
80. J. Jeong, M. Usman, Y. Li, X.Z. Zhou, K.P. Lu. Pin1-Catalyzed conformation changes regulate protein ubiquitination and degradation. Cells, 2024. [DOI]
81. Y.M. Lee, Y.-C. Liou. Gears-in-motion: the interplay of WW and PPIase domains in Pin1. Front. Oncol., 2018
82. R. Ranganathan, K.P. Lu, T. Hunter, J.P. Noel. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell, 1997. [DOI | PubMed]
83. Y.M. Lee, D.E.-J. Teoh, K. Yeung, Y.-C. Liou. The kingdom of the prolyl-isomerase Pin1: the structural and functional convergence and divergence of Pin1. Front. Cell Dev. Biol., 2022
84. W. Wang, Q. Jiang, J. Tao, Z. Zhang, G. Liu, B. Qiu, Q. Hu, Y. Zhang, C. Xie, J. Song, G. Jiang, H. Zhong, Y. Zou, J. Li, S. lv. A structure-based approach to discover a potential isomerase Pin1 inhibitor for cancer therapy using computational simulation and biological studies. Comput. Biol. Chem., 2025. [DOI]
85. M. Tian, X. Wang, G. Tang, G. Cui, J. Zhou, J. Jin, B. Xu. Discovery of novel pyrimidine derivatives as human Pin1 covalent inhibitors. ACS Med. Chem. Lett., 2025. [DOI | PubMed]
86. W. Pu, X. Shen, X. Fan, Y. Zheng, X. Liu, J. Li, J.-K. Zhou, J. He, R. Wei, Y. Gong, Q. Zheng, Y. Luo, Y. Guo, M. Ai, Y. Ming, Z. Ye, Y. Zhao, C. Wang, Y. Peng. Structure-guided optimization and preclinical evaluation of 6-O-Benzylguanine-Based Pin1 inhibitor for hepatocellular carcinoma treatment. J. Med. Chem., 2025. [DOI | PubMed]
87. C. Dubiella, B.J. Pinch, K. Koikawa, D. Zaidman, E. Poon, T.D. Manz, B. Nabet, S. He, E. Resnick, A. Rogel, E.M. Langer, C.J. Daniel, H.-S. Seo, Y. Chen, G. Adelmant, S. Sharifzadeh, S.B. Ficarro, Y. Jamin, B. Martins da Costa, M.W. Zimmerman, X. Lian, S. Kibe, S. Kozono, Z.M. Doctor, C.M. Browne, A. Yang, L. Stoler-Barak, R.B. Shah, N.E. Vangos, E.A. Geffken, R. Oren, E. Koide, S. Sidi, Z. Shulman, C. Wang, J.A. Marto, S. Dhe-Paganon, T. Look, X.Z. Zhou, K.P. Lu, R.C. Sears, L. Chesler, N.S. Gray, N. London. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat. Chem. Biol., 2021. [DOI | PubMed]
88. X.Z. Zhou, K.P. Lu. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat. Rev. Cancer, 2016. [DOI | PubMed]
89. Z. Sun, Z. Huang, D.D. Zhang. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-Dependent antioxidant response. PLoS One, 2009. [DOI]
90. S. Saeidi, S.-J. Kim, Y.N. Guillen-Quispe, A.S.V. Jagadeesh, H. Han, S.H. Kim, X. Zhong, J.-Y. Piao, S.-J. Kim, J. Jeong, Y.J. Shin, Y.J. Cha, H.-B. Lee, W. Han, S.-H. Min, W. Tian, H. Kitamura, Y.-J. Surh. Peptidyl-prolyl cis-trans isomerase NIMA-Interacting 1 directly binds and stabilizes Nrf2 in breast cancer. FASEB J., 2022. [DOI]
91. C. Liang, S. Shi, M. Liu, Y. Qin, Q. Meng, J. Hua, S. Ji, Y. Zhang, J. Yang, J. Xu, Q. Ni, M. Li, X. Yu. PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract kras-induced mitochondrial respiratory injury in pancreatic cancer cells. Cancer Res., 2019. [DOI | PubMed]
92. A. Ozleyen, G.N. Duran, S. Donmez, M. Ozbil, R.G. Doveston, T.B. Tumer. Identification and inhibition of PIN1-NRF2 protein–protein interactions through computational and biophysical approaches. Sci. Rep., 2025. [DOI | PubMed]
93. T. Eichner, S. Kutter, W. Labeikovsky, V. Buosi, D. Kern. Molecular mechanism of Pin1–Tau recognition and catalysis. J. Mol. Biol., 2016. [DOI | PubMed]
94. X.-R. Chen, K. Dixit, Y. Yang, M.I. McDermott, H.T. Imam, V.A. Bankaitis, T.I. Igumenova. A novel bivalent interaction mode underlies a non-catalytic mechanism for Pin1-mediated protein kinase C regulation. eLife, 2024. [DOI]
95. A. Kopacz, D. Kloska, H.J. Forman, A. Jozkowicz, A. Grochot-Przeczek. Beyond repression of Nrf2: an update on Keap1. Free Radic. Biol. Med., 2020. [DOI | PubMed]
96. Z. Zhang, Q. Hu, S. Ye, L. Xiang. Inhibition of the PIN1-NRF2/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells, acta biochim. Biophys. Sin. (Shanghai)., 2022. [DOI]
97. C. Liang, Z. Rong, A. Tuerhong, Q. Meng, J. Hua, J. Liu, B. Zhang, W. Wang, X. Yu, S. Shi, J. Xu. Mechanical regulation of redox balance via the induction of the PIN1/NRF2/ARE axis in pancreatic cancer. Int. J. Mol. Sci., 2023. [DOI]
98. S. Saeidi, S.-J. Kim, H. Han, S.H. Kim, J. Zheng, H.-B. Lee, W. Han, D.-Y. Noh, H.-K. Na, Y.-J. Surh. H-Ras induces Nrf2-Pin1 interaction: implications for breast cancer progression. Toxicol. Appl. Pharmacol., 2020. [DOI]
99. T. Ishii, E. Warabi, G.E. Mann. Stress activated MAP kinases and cyclin-dependent kinase 5 mediate nuclear translocation of Nrf2 via Hsp90α-Pin1-Dynein motor transport machinery. Antioxidants, 2023. [DOI]
100. H. Yu, G. Jiang, W. Hu, C. Xu. Pin1 aggravates renal injury induced by ischemia and reperfusion in rats via Nrf2/HO-1 mediated endoplasmic reticulum stress. Acta Cir. Bras., 2022
101. S.E. Kim, M.Y. Lee, S.C. Lim, T.T. Hien, J.W. Kim, S.-G. Ahn, J.-H. Yoon, S.K. Kim, H.S. Choi, K.W. Kang. Role of Pin1 in neointima formation: down-regulation of Nrf2-dependent heme oxygenase-1 expression by Pin1. Free Radic. Biol. Med., 2010. [DOI | PubMed]
102. W.-J. Keune, D.R. Jones, Y. Bultsma, L. Sommer, X.Z. Zhou, K.P. Lu, N. Divecha. Regulation of Phosphatidylinositol-5-Phosphate signaling by Pin1 determines sensitivity to oxidative stress. Sci. Signal., 2012. [DOI]
103. X.J. Wang, J.D. Hayes, C.J. Henderson, C.R. Wolf. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci., 2007. [DOI | PubMed]
104. A. Kobayashi, M.-I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, M. Yamamoto. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-Based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol., 2004. [DOI | PubMed]
105. P. Canning, C.D.O. Cooper, T. Krojer, J.W. Murray, A.C.W. Pike, A. Chaikuad, T. Keates, C. Thangaratnarajah, V. Hojzan, B.D. Marsden, O. Gileadi, S. Knapp, F. von Delft, A.N. Bullock. Structural basis for Cul3 protein assembly with the BTB-kelch family of E3 ubiquitin ligases. J. Biol. Chem., 2013. [DOI | PubMed]
106. E.S. Zimmerman, B.A. Schulman, N. Zheng. Structural assembly of cullin-RING ubiquitin ligase complexes. Curr. Opin. Struct. Biol., 2010. [DOI | PubMed]
107. M. Furukawa, Y. Xiong. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the cullin 3-Roc1 ligase. Mol. Cell Biol., 2005. [DOI | PubMed]
108. D.M. Duda, L.A. Borg, D.C. Scott, H.W. Hunt, M. Hammel, B.A. Schulman. Structural insights into NEDD8 activation of Cullin-RING ligases: conformational control of conjugation. Cell, 2008. [DOI | PubMed]
109. T. Fukutomi, K. Takagi, T. Mizushima, N. Ohuchi, M. Yamamoto. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1. Mol. Cell Biol., 2014. [DOI | PubMed]
110. Y. Horie, T. Suzuki, J. Inoue, T. Iso, G. Wells, T.W. Moore, T. Mizushima, A.T. Dinkova-Kostova, T. Kasai, T. Kamei, S. Koshiba, M. Yamamoto. Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & latch mechanism. Commun. Biol., 2021. [DOI | PubMed]
111. R.J. Deshaies, C.A.P. Joazeiro. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem., 2009. [DOI | PubMed]
112. R.B. Damgaard. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ., 2021. [DOI | PubMed]
113. L. Baird, M. Yamamoto. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell Biol., 2020. [DOI]
114. T. Suzuki, J. Takahashi, M. Yamamoto. Molecular basis of the KEAP1-NRF2 signaling pathway. Mol. Cells, 2023. [DOI | PubMed]
115. P. Canning, A.N. Bullock. New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases. Biochem. Soc. Trans., 2014. [DOI | PubMed]
116. G. Ralf, K. Ludwig, A.D. L, B.-O. Amit, G. Gavin, S. Krzysztof, T. Carlo, S.M. T, Y. Minhua, S.S. I, D.K. T. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med., 2012. [DOI | PubMed]
117. F.R. J, M.D. H, P.J. Theodore, H. Michael, H. Eva, K. Mariko, Y. Minhua, R. Kartik, N. Mark, S.M. T, V. Vissia, D.K. T. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med., 2025. [DOI]
118. M. Carey, B. Li, J.L. Workman. RSC exploits histone acetylation to abrogate the nucleosomal block to RNA polymerase II elongation. Mol. Cell, 2006. [DOI | PubMed]
119. D.R. Lynch, M.P. Chin, M.B. Delatycki, S.H. Subramony, M. Corti, J.C. Hoyle, S. Boesch, W. Nachbauer, C. Mariotti, K.D. Mathews, P. Giunti, G. Wilmot, T. Zesiewicz, S. Perlman, A. Goldsberry, M. O’Grady, C.J. Meyer. Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe Study). Ann. Neurol., 2021. [DOI | PubMed]
120. D.R. Lynch, J. Farmer, L. Hauser, I.A. Blair, Q.Q. Wang, C. Mesaros, N. Snyder, S. Boesch, M. Chin, M.B. Delatycki, P. Giunti, A. Goldsberry, C. Hoyle, M.G. McBride, W. Nachbauer, M. O’Grady, S. Perlman, S.H. Subramony, G.R. Wilmot, T. Zesiewicz, C. Meyer. Safety, pharmacodynamics, and potential benefit of omaveloxolone in friedreich ataxia. Ann. Clin. Transl. Neurol., 2019. [DOI | PubMed]
121. Sreeja Gopal, Alvydas Mikulskis, Ralf Gold, Robert J. Fox, Katherine T. Dawson, Lakshmi Amaravadi. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the phase 3 DEFINE and CONFIRM studies. Multiple Sclerosis J., 2017. [DOI]
122. L. Hauer, J. Sellner. Diroximel fumarate as a novel oral immunomodulating therapy for relapsing forms of multiple sclerosis: a review on the emerging data. Drug Des. Dev. Ther., 2022. [DOI]
123. K.R. Edwards, A. Kamath, J. Button, V. Kamath, J.P. Mendoza, B. Zhu, T. Plavina, C. Woodward, N. Penner. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. Mult. Scler. Relat. Disord., 2021. [DOI]
124. S. Dayalan Naidu, A.T. Dinkova-Kostova. Omaveloxolone (SkyclarysTM) for patients with Friedreich’s ataxia. Trends Pharmacol. Sci., 2023. [DOI | PubMed]
125. Hongmin Li, Mengting Hong, Yikun Liu, Shafiq ur Rahman, Xuejuan Li, Feng Zheng. Bardoxolone methyl triggers Ferroptosis in cardiomyocytes. Hum. Exp. Toxicol., 2025. [DOI]
126. Y. Zhang, P. Talalay, C.G. Cho, G.H. Posner. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci., 1992. [DOI | PubMed]
127. Y. Yagishita, J.W. Fahey, A.T. Dinkova-Kostova, T.W. Kensler. Broccoli or sulforaphane: is it the source or dose that matters?. Molecules, 2019. [DOI]
128. A.T. Dinkova-Kostova, J.W. Fahey, R. V Kostov, T.W. Kensler. KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. Trends Food Sci. Technol., 2017. [DOI | PubMed]
129. J.W. Fahey, T.W. Kensler. The challenges of designing and implementing clinical trials with broccoli sprouts… and turning evidence into public health action. Front. Nutr., 2021
130. G. Rachakonda, Y. Xiong, K.R. Sekhar, S.L. Stamer, D.C. Liebler, M.L. Freeman. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol., 2008. [DOI | PubMed]
131. J.L. Castaño, V. Arenas, J.J. Domínguez, S. Fernández-Luis, L. Yáñez, C. Pipaón. Inhibition of NEDDylation enhances the cytostatic effect of rohinitib on chronic lymphocytic leukemia cells. Biomed. Pharmacother., 2025. [DOI]
132. F.A. Aiello, L. D’Archivio, M. Attili, E. Ferraro, E. Macrì, R. Mazzocchi, M. Cassandri, S. Pomella, V. Tocco, M. Pezzullo, C. De Stefanis, S. Codenotti, G. Barillari, C. Marchese, A. Fanzani, F. Megiorni, J. Shipley, M. Yohe, S.A. Gatz, P.J. Houghton, G. Cenci, C. Quintarelli, F. Locatelli, F. Marampon, B. De Angelis, R. Rota. Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3–FOXO1 rhabdomyosarcoma. Cell Death Discov., 2025. [DOI | PubMed]
133. J.-L. Huo, W. Fu, Q. Feng, S. Pan, D. Liu, Z. Liu. Blockade of neddylation through targeted inhibition of DCN1 alleviates renal fibrosis. Clin. Sci., 2025. [DOI]
134. R. Pillai, M. Hayashi, A.-M. Zavitsanou, T. Papagiannakopoulos. NRF2: KEAPing tumors protected. Cancer Discov., 2022. [DOI | PubMed]
135. Y. Yagishita, D. V Chartoumpekis, T.W. Kensler, N. Wakabayashi. NRF2 and the moirai: life and death decisions on cell fates. Antioxid. Redox Signaling, 2022. [DOI]
136. M. Rojo de la Vega, E. Chapman, D.D. Zhang. NRF2 and the hallmarks of cancer. Cancer Cell, 2018. [DOI | PubMed]
137. K. Tsuchida, T. Tsujita, M. Hayashi, A. Ojima, N. Keleku-Lukwete, F. Katsuoka, A. Otsuki, H. Kikuchi, Y. Oshima, M. Suzuki, M. Yamamoto. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic. Biol. Med., 2017. [DOI | PubMed]
138. S. Ijaz, J. Iqbal, B.A. Abbasi, F. Zarshan, T. Yaseen, Z. Ullah, S. Uddin, S. Kanwal, T. Mahmood, W.N. Setzer, J. Sharifi-Rad, D. Calina. Bruceantin and brusatol: molecular insights and therapeutic promise of quassinoids in cancer drug discovery. Arch. Pharm. (Weinheim), 2025. [DOI]
139. D. Zhang, Z. Hou, K.E. Aldrich, L. Lockwood, A.L. Odom, K.T. Liby. A novel Nrf2 pathway inhibitor sensitizes Keap1-Mutant lung cancer cells to chemotherapy. Mol. Cancer Therapeut., 2021. [DOI]
140. Z. Hou, L. Lockwood, D. Zhang, C.J. Occhiuto, L. Mo, K.E. Aldrich, H.E. Stoub, K.A. Gallo, K.T. Liby, A.L. Odom. Exploring structural effects in a new class of NRF2 inhibitors. RSC Med. Chem., 2023. [DOI | PubMed]
141. M. Lu, T. Liu, Q. Jiao, J. Ji, M. Tao, Y. Liu, Q. You, Z. Jiang. Discovery of a Keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway. Eur. J. Med. Chem., 2018. [DOI | PubMed]
142. G. Du, J. Jiang, N.J. Henning, N. Safaee, E. Koide, R.P. Nowak, K.A. Donovan, H. Yoon, I. You, H. Yue, N.A. Eleuteri, Z. He, Z. Li, H.T. Huang, J. Che, B. Nabet, T. Zhang, E.S. Fischer, N.S. Gray. Exploring the target scope of KEAP1 E3 ligase-based PROTACs. Cell Chem. Biol., 2022. [DOI | PubMed]
143. J. Ji, S. Ma, Y. Zhu, J. Zhao, Y. Tong, Q. You, Z. Jiang. ARE-PROTACs enable Co-degradation of an Nrf2–MafG heterodimer. J. Med. Chem., 2023. [DOI | PubMed]
144. C. Housand, N. Roy, T. Wyseure, C. Eissler, H. Ruehs, C. Niederalt, C. Zieschang, M. Mata, R. Samadani, J. Bothos, L. Lu, J. Goldberg, P.N. Morcos. Abstract 4349: translational pharmacokinetic/pharmacodynamic (PK/PD) modeling for VVD-130037, a novel, first-in-class covalent small molecule Kelch-like ECH-Associated protein 1 (KEAP1) activator. Cancer Res., 2025. [DOI]
145. V. Aarnio, M. Storvik, M. Lehtonen, S. Asikainen, K. Reisner, J. Callaway, M. Rudgalvyte, M. Lakso, G. Wong. Fatty acid composition and gene expression profiles are altered in aryl hydrocarbon receptor-1 mutant Caenorhabditis elegans. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2010. [DOI | PubMed]
146. J.W. Kaspar, S.K. Niture, A.K. Jaiswal. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med., 2009. [DOI | PubMed]
147. Y. Li, J.D. Paonessa, Y. Zhang. Mechanism of chemical activation of Nrf2. PLoS One, 2012. [DOI]
148. J.Y. Lo, B.N. Spatola, S.P. Curran. WDR23 regulates NRF2 independently of KEAP1. PLoS Genet., 2017. [DOI]
149. J. Lee, P. Zhou. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell, 2007. [DOI | PubMed]
150. C. Duangjan, T.E. Arpawong, B.N. Spatola, S.P. Curran. Hepatic WDR23 proteostasis mediates insulin homeostasis by regulating insulin-degrading enzyme capacity. GeroScience, 2024. [DOI | PubMed]
151. N. Vo, R.H. Goodman. CREB-Binding protein and p300 in transcriptional regulation. J. Biol. Chem., 2001. [DOI | PubMed]
152. D.A. Bose, G. Donahue, D. Reinberg, R. Shiekhattar, R. Bonasio, S.L. Berger. RNA binding to CBP stimulates histone acetylation and transcription. Cell, 2017. [DOI | PubMed]
153. H.-L. Hung, A.Y. Kim, W. Hong, C. Rakowski, G.A. Blobel. Stimulation of NF-E2 DNA binding by CREB-Binding protein (CBP)-mediated acetylation. J. Biol. Chem., 2001. [DOI | PubMed]
154. Y. Kawai, L. Garduño, M. Theodore, J. Yang, I.J. Arinze. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem., 2011. [DOI | PubMed]
155. Z. Sun, Y.E. Chin, D.D. Zhang. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol. Cell Biol., 2009. [DOI | PubMed]
156. A. Ganner, Z.-C. Pfeiffer, L. Wingendorf, S. Kreis, M. Klein, G. Walz, E. Neumann-Haefelin. The acetyltransferase p300 regulates NRF2 stability and localization. Biochem. Biophys. Res. Commun., 2020. [DOI | PubMed]
157. P. Nioi, T. Nguyen, P.J. Sherratt, C.B. Pickett. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol. Cell Biol., 2005. [DOI | PubMed]
158. H. Sekine, K. Okazaki, N. Ota, H. Shima, Y. Katoh, N. Suzuki, K. Igarashi, M. Ito, H. Motohashi, M. Yamamoto. The mediator subunit MED16 transduces NRF2-Activating signals into antioxidant gene expression. Mol. Cell Biol., 2016. [DOI | PubMed]
159. J.D. Hayes, A.T. Dinkova-Kostova. Epigenetic control of NRF2-Directed cellular antioxidant status in dictating life-death decisions. Mol. Cell, 2017. [DOI | PubMed]
160. Y. Katoh, K. Itoh, E. Yoshida, M. Miyagishi, A. Fukamizu, M. Yamamoto. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells, 2001. [DOI | PubMed]
161. N.C. Karunatilleke, A. Brickenden, W.-Y. Choy. Molecular basis of the interactions between the disordered Neh4 and Neh5 domains of Nrf2 and CBP/p300 in oxidative stress response. Protein Sci., 2024. [DOI]
162. J. Zhang, T. Ohta, A. Maruyama, T. Hosoya, K. Nishikawa, J.M. Maher, S. Shibahara, K. Itoh, M. Yamamoto. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol. Cell Biol., 2006. [DOI | PubMed]
163. J. Zhang, T. Hosoya, A. Maruyama, K. Nishikawa, J.M. Maher, T. Ohta, H. Motohashi, A. Fukamizu, S. Shibahara, K. Itoh, M. Yamamoto. Nrf2 Neh5 domain is differentially utilized in the transactivation of cytoprotective genes. Biochem. J., 2007. [DOI | PubMed]
164. J.-H. Kim, S. Yu, J.D. Chen, A.N. Kong. The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains. Oncogene, 2013. [DOI | PubMed]
165. S.H. Ki, I.J. Cho, D.W. Choi, S.G. Kim. Glucocorticoid receptor (GR)-associated SMRT binding to C/EBPβ TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression. Mol. Cell Biol., 2005. [DOI | PubMed]
166. MdM. Alam, K. Okazaki, L.T.T. Nguyen, N. Ota, H. Kitamura, S. Murakami, H. Shima, K. Igarashi, H. Sekine, H. Motohashi. Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. J. Biol. Chem., 2017. [DOI | PubMed]
167. N. Mercado, R. Thimmulappa, C.M.R. Thomas, P.S. Fenwick, K.K. Chana, L.E. Donnelly, S. Biswal, K. Ito, P.J. Barnes. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun., 2011. [DOI | PubMed]
168. X. Yang, S.H. Park, H.C. Chang, J.S. Shapiro, A. Vassilopoulos, K.T. Sawicki, C. Chen, M. Shang, P.W. Burridge, C.L. Epting, L.D. Wilsbacher, S. Jenkitkasemwong, M. Knutson, D. Gius, H. Ardehali. Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. J. Clin. Investig., 2017. [DOI | PubMed]
169. E.J. Perez Lao, E. Fagerli, F. Ferrier, J.I. Young, M.A. Perez-Pinzon. Regulatory dynamics of Nrf2 with sirtuins in the brain: exploring cellular metabolism, synaptic plasticity, and defense mechanisms. J. Neurochem., 2025. [DOI]
170. Z. Li, J. Xing. Role of sirtuins in cerebral ischemia-reperfusion injury: mechanisms and therapeutic potential. Int. J. Biol. Macromol., 2025. [DOI]
171. M. Cui, Y. An, J. Zhao, M. Hui, Z. Xiong, B. Guan, Y. Shen, Y. Zou, C. Li, R. Wang. Dahuang gancao decoction suppresses ferroptosis via SIRT3-mediated NRF2 deacetylation in acute kidney injury. Phytomedicine, 2026. [DOI]
172. X. Liu, H. Li, L. Liu, Y. Lu, Y. Gao, P. Geng, X. Li, B. Huang, Y. Zhang, J. Lu. Methylation of arginine by PRMT1 regulates Nrf2 transcriptional activity during the antioxidative response. Biochim. Biophys. Acta Mol. Cell Res., 2016. [DOI]
173. M.T. Malloy, D.J. McIntosh, T.S. Walters, A. Flores, J.S. Goodwin, I.J. Arinze. Trafficking of the transcription factor Nrf2 to promyelocytic leukemia-nuclear bodies: implications for degradation of NRF2 in the nucleus. J. Biol. Chem., 2013. [DOI | PubMed]
174. D.J. McIntosh, T.S. Walters, I.J. Arinze, J. Davis. Arkadia (RING finger protein 111) mediates sumoylation-dependent stabilization of Nrf2 through K48-Linked ubiquitination. Cell. Physiol. Biochem., 2018. [DOI | PubMed]
175. T.S. Waltersa, D.J. McIntosha, S.M. Ingram, L. Tillery, E.D. Motley, I.J. Arinze, S. Misra. SUMO-modification of human Nrf2 at K110 and K533 regulates its nucleocytoplasmic localization, stability and transcriptional activity. Cell. Physiol. Biochem., 2021. [DOI]
176. H. Guo, J. Xu, Q. Zheng, J. He, W. Zhou, K. Wang, X. Huang, Q. Fan, J. Ma, J. Cheng, W. Mei, R. Xing, R. Cai. NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis. Cancer Lett., 2019. [DOI | PubMed]
177. K. Ramani, M.L. Tomasi, H. Yang, K. Ko, S.C. Lu. Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis. J. Biol. Chem., 2012. [DOI | PubMed]
178. X. He, Q. Lai, C. Chen, N. Li, F. Sun, W. Huang, S. Zhang, Q. Yu, P. Yang, F. Xiong, Z. Chen, Q. Gong, B. Ren, J. Weng, D.L. Eizirik, Z. Zhou, C.-Y. Wang. Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function. Diabetologia, 2018. [DOI | PubMed]
179. Q. Shi, W. Yao, W. Zhang, J. Xu, X. Wang, X. Wei, S. Hu, Q. Fan, H. Yang, X. Wu, R. Cai. Nrf2 de-SUMOylation alleviates myocardial ischemia-reperfusion injury (MIRI) by attenuating myocardial ferroptosis in mice. Redox Rep., 2026. [DOI]
180. B. Dieter, E. Johnson, H. Medford, L. Miller, C. Vella, S. Marsh. O-GlcNAc plays a role in Nrf2 regulation in the myocardium. FASEB J., 2015. [DOI]
181. P. Chen, T.J. Smith, J. Wu, P.F. Siesser, B.J. Bisnett, F. Khan, M. Hogue, E. Soderblom, F. Tang, J.R. Marks, M.B. Major, B.M. Swarts, M. Boyce, J. Chi. Glycosylation of KEAP1 links nutrient sensing to redox stress signaling. EMBO J., 2017. [DOI | PubMed]
182. R.M. Costa, M.C. Dias, J. V Alves, J.L.M. Silva, D. Rodrigues, J.F. Silva, H.D.C. Francescato, L.N.Z. Ramalho, T.M. Coimbra, R.C. Tostes. Pharmacological activation of nuclear factor erythroid 2-related factor-2 prevents hyperglycemia-induced renal oxidative damage: possible involvement of O-GlcNAcylation. Biochem. Pharmacol., 2024. [DOI]
183. W. Dai, X. Jin, B. Jiang, W. Chen, Z. Ji, X. Xu, M. Tang, K. Dai, L. Han. Elevated O-GlcNAcylation promotes malignant phenotypes of hypopharyngeal squamous cell carcinoma by stabilizing Nrf2 through regulation of the PI3K/Akt pathway. Anti Cancer Agents Med. Chem., 2020. [DOI]
184. Y. Zhang, C. Sun, L. Ma, G. Xiao, Y. Gu, W. Yu. O-GlcNAcylation promotes malignancy and cisplatin resistance of lung cancer by stabilising NRF2. Clin. Transl. Med., 2024. [DOI]
185. I. Matic, J. Schimmel, I.A. Hendriks, M.A. van Santen, F. van de Rijke, H. van Dam, F. Gnad, M. Mann, A.C.O. Vertegaal. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell, 2010. [DOI | PubMed]
186. S. Yang, A. Galanis, J. Witty, A.D. Sharrocks. An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J., 2006. [DOI | PubMed]
187. T. Nguyen, P. Nioi, C.B. Pickett. The Nrf2-Antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem., 2009. [DOI | PubMed]
188. A. Flotho, F. Melchior. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem., 2013. [DOI]
189. E.S. Johnson. Protein modification by SUMO. Annu. Rev. Biochem., 2004. [DOI]
190. K. Uzunova, K. Göttsche, M. Miteva, S.R. Weisshaar, C. Glanemann, M. Schnellhardt, M. Niessen, H. Scheel, K. Hofmann, E.S. Johnson, G.J.K. Praefcke, R.J. Dohmen. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem., 2007. [DOI | PubMed]
191. A.M. Sriramachandran, R.J. Dohmen. SUMO-Targeted ubiquitin ligases. Biochim. Biophys. Acta Mol. Cell Res., 2014. [DOI]
192. H. Sun, T. Hunter. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search. J. Biol. Chem., 2012. [DOI | PubMed]
193. G.W. Hart, C. Slawson, G. Ramirez-Correa, O. Lagerlof. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem., 2011. [DOI]
194. M.R. Bond, J.A. Hanover. A little sugar goes a long way: the cell biology of O-GlcNAc. JCB (J. Cell Biol.), 2015. [DOI | PubMed]
195. Q. Zeidan, G.W. Hart. The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J. Cell Sci., 2010. [DOI | PubMed]
196. X. Yang, K. Qian. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat. Rev. Mol. Cell Biol., 2017. [DOI | PubMed]
197. P. Banerjee, G.W. Hart. Handbook of Glycosyltransferases and Related Genes, 2014. [DOI]
198. G. Duan, D. Walther. The roles of post-translational modifications in the context of protein interaction networks. PLoS Comput. Biol., 2015. [DOI]
199. S. Wang, A.O. Osgood, A. Chatterjee. Uncovering post-translational modification-associated protein–protein interactions. Curr. Opin. Struct. Biol., 2022. [DOI]
200. J. De Las Rivas, C. Fontanillo. Protein–protein interaction networks: unraveling the wiring of molecular machines within the cell. Brief. Funct. Genom., 2012. [DOI]
201. A.P. Tay, A. Liang, M.R. Wilkins, C.N.I. Pang. Visualizing post-translational modifications in protein interaction networks using PTMOracle. Curr. Protoc. Bioinform., 2019. [DOI]
202. H. Huang, C.N. Arighi, K.E. Ross, J. Ren, G. Li, S.-C. Chen, Q. Wang, J. Cowart, K. Vijay-Shanker, C.H. Wu. iPTMnet: an integrated resource for protein post-translational modification network discovery. Nucleic Acids Res., 2018. [DOI | PubMed]
203. A. Elangovan, Y. Li, D.E. V Pires, M.J. Davis, K. Verspoor. Large-scale protein-protein post-translational modification extraction with distant supervision and confidence calibrated BioBERT. BMC Bioinf., 2022. [DOI]
204. A. Dinkova-Kostova. KEAP1/NRF2 as a druggable target. Arh. Farm. (Belgr)., 2023. [DOI]
205. M. Konstantinidou, M.R. Arkin. Molecular glues for protein-protein interactions: progressing toward a new dream. Cell Chem. Biol., 2024. [DOI | PubMed]
206. M. Falcicchio, J.A. Ward, S. Macip, R.G. Doveston. Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer. Cell Death Discov., 2020. [DOI | PubMed]